{"id":125277,"date":"2021-10-29T11:04:35","date_gmt":"2021-10-29T15:04:35","guid":{"rendered":"https:\/\/44.250.171.167\/?p=125277"},"modified":"2021-10-29T12:24:53","modified_gmt":"2021-10-29T16:24:53","slug":"key-highlights-from-dr-reddys-q2-2022-earnings-results","status":"publish","type":"post","link":"https:\/\/alphastreet.com\/india\/key-highlights-from-dr-reddys-q2-2022-earnings-results\/","title":{"rendered":"Key highlights from Dr Reddy\u2019s Q2 2022 earnings results"},"content":{"rendered":"\n<p>Dr Reddy\u2019s Laboratories<a href=\"https:\/\/44.250.171.167\/?post_type=post&amp;s=reddy\"> (<strong>NSE: <\/strong>DRREDDY)<\/a> reported its second-quarter financial results for the period ended September 30, 2021.<\/p>\n\n\n\n<p>The company had total revenue of \u20b957.6 billion with a growth of 18% year on year.<\/p>\n\n\n\n<p>Dr Reddy&#8217;s reported a net profit of \u20b99.92 billion or \u20b959.65 per share compared to \u20b97.62 billion or \u20b945.83 in the same quarter of the previous year.<\/p>\n\n\n\n<p>The global generics business posted a growth of 19% year on year. The Indian business saw sales jump 25% on-year to  \u20b911.4&nbsp;billion.<\/p>\n\n\n\n<p>\u201cI am pleased with the improvement in the financial performance across our businesses. While we continue to strengthen our core businesses of generics and APIs, we are also making investments in our long-term growth drivers and deeper innovation capabilities,\u201d said G.V. Prasad, co-chairman and managing director at Dr Reddy\u2019s.<\/p>\n\n\n\n<p><\/p>\n\n\n\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Dr Reddy\u2019s Laboratories (NSE: DRREDDY) reported its second-quarter financial results for the period ended September 30, 2021. The company had total revenue of \u20b957.6 billion with a growth of 18% year on year. Dr Reddy&#8217;s reported a net profit of \u20b99.92 billion or \u20b959.65 per share compared to \u20b97.62 billion or \u20b945.83 in the same [&hellip;]<\/p>\n","protected":false},"author":83,"featured_media":125269,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[392,5747],"tags":[9138,1408,1115],"class_list":["post-125277","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-earnings","category-healthcare-stocks","tag-pharma","tag-pharma-stocks","tag-pharmaceuticals"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2021\/10\/Earnings-Coverage.jpg","jetpack_likes_enabled":false,"jetpack-related-posts":[{"id":143632,"url":"https:\/\/alphastreet.com\/india\/dr-reddys-laboratories-one-of-the-major-player-in-generic-segment\/","url_meta":{"origin":125277,"position":0},"title":"Dr. Reddy&#8217;s Laboratories: One Of The Major Player In Generic Segment","author":"Hardik Bhandare","date":"April 11, 2023","format":false,"excerpt":"\u201cWe are progressing well on our pipeline products. The number of filings in several of our key markets have been improving. The ANDA and DMF filings are expected to significantly improve during Q4. We are evaluating several inorganic opportunities across businesses in line with our strategy. We believe, all of\u2026","rel":"","context":"In &quot;Research Summary&quot;","block_context":{"text":"Research Summary","link":"https:\/\/alphastreet.com\/india\/category\/research-summary\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/04\/898c572d-b97a-4c10-acd3-c5f4d9ad88be-1-1.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/04\/898c572d-b97a-4c10-acd3-c5f4d9ad88be-1-1.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/04\/898c572d-b97a-4c10-acd3-c5f4d9ad88be-1-1.jpg?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/04\/898c572d-b97a-4c10-acd3-c5f4d9ad88be-1-1.jpg?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/04\/898c572d-b97a-4c10-acd3-c5f4d9ad88be-1-1.jpg?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/04\/898c572d-b97a-4c10-acd3-c5f4d9ad88be-1-1.jpg?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":142958,"url":"https:\/\/alphastreet.com\/india\/earnings-dr-reddys-laboratories-ltd-nsedrreddy-q3fy23-results-out-total-income-rise-27-yoy\/","url_meta":{"origin":125277,"position":1},"title":"Earnings | Dr. Reddy&#8217;s Laboratories Ltd. (NSE:DRREDDY): Q3FY23 Results Out; Total Income rise 27% YoY","author":"Divyansh_Kasana","date":"February 28, 2023","format":false,"excerpt":"Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY) is a multinational pharmaceutical company based in Hyderabad, India. The company was founded in 1984 and has since grown to become a leading player in the global pharmaceutical industry. Dr. Reddy's Laboratories specializes in the development, manufacturing, and marketing of generic drugs, active pharmaceutical ingredients\u2026","rel":"","context":"In &quot;Earnings&quot;","block_context":{"text":"Earnings","link":"https:\/\/alphastreet.com\/india\/category\/earnings\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":139213,"url":"https:\/\/alphastreet.com\/india\/infographic-ltd-nse-drreddy-q3-fy23-results-total-income-rises-7-47-qoq\/","url_meta":{"origin":125277,"position":2},"title":"Infographic  Ltd.(NSE: DRREDDY) | Q3 FY23 Results | Total Income rises +7.47% qoq","author":"Divyansh_Kasana","date":"January 25, 2023","format":false,"excerpt":"Dr. Reddy's Laboratories (NSE: DRREDDY) is an Indian multinational pharmaceutical company. Founded in 1984, the company primarily develops and sells a wide range of generic and over-the-counter drugs, as well as active pharmaceutical ingredients, and biopharmaceuticals. The company has operations in over 100 countries, with a focus on the developing\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/01\/5b3e3ff5-0abc-4a25-9003-fdf05b414deb.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/01\/5b3e3ff5-0abc-4a25-9003-fdf05b414deb.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/01\/5b3e3ff5-0abc-4a25-9003-fdf05b414deb.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/01\/5b3e3ff5-0abc-4a25-9003-fdf05b414deb.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/01\/5b3e3ff5-0abc-4a25-9003-fdf05b414deb.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/01\/5b3e3ff5-0abc-4a25-9003-fdf05b414deb.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":135275,"url":"https:\/\/alphastreet.com\/india\/dr-reddys-laboratories-limited-q2fy23-net-profit-increased-by-12\/","url_meta":{"origin":125277,"position":3},"title":"Dr. Reddy&#8217;s Laboratories Limited Q2FY23; Net Profit Increased By 12%","author":"Hardik Bhandare","date":"October 31, 2022","format":false,"excerpt":"Dr. Reddy's Laboratories Limited (NSE: DRREDDY) reported Revenue from Operations for Q2 FY23 of \u20b963,318 Crore up from \u20b957,896 Crore year on year, a growth of 9%. Global Generics Segment surged by 18% to \u20b956,009 Crore. Consolidated Net Profit of \u20b911,142 up 12% from \u20b99,958 Crore in the same quarter\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2022\/10\/b8ce7e0b-90f6-4268-bbe3-939db5bfaaa8-scaled.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2022\/10\/b8ce7e0b-90f6-4268-bbe3-939db5bfaaa8-scaled.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2022\/10\/b8ce7e0b-90f6-4268-bbe3-939db5bfaaa8-scaled.jpg?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2022\/10\/b8ce7e0b-90f6-4268-bbe3-939db5bfaaa8-scaled.jpg?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2022\/10\/b8ce7e0b-90f6-4268-bbe3-939db5bfaaa8-scaled.jpg?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2022\/10\/b8ce7e0b-90f6-4268-bbe3-939db5bfaaa8-scaled.jpg?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":145690,"url":"https:\/\/alphastreet.com\/india\/earnings-summary-of-dr-reddy-s-laboratories-limited-for-q4-fy23\/","url_meta":{"origin":125277,"position":4},"title":"Earnings Summary Of Dr Reddy &#8216;s Laboratories Limited For Q4 FY23","author":"Hardik Bhandare","date":"May 10, 2023","format":false,"excerpt":"Dr. Reddy's Laboratories Limited is an Indian multinational pharmaceutical company with a presence in over 25 countries. It was founded in 1984 and has its headquarters in Hyderabad, India. Dr. Reddy's is a research-driven company with a focus on developing and manufacturing high-quality pharmaceutical products. The company operates in three\u2026","rel":"","context":"In &quot;Earnings&quot;","block_context":{"text":"Earnings","link":"https:\/\/alphastreet.com\/india\/category\/earnings\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/898c572d-b97a-4c10-acd3-c5f4d9ad88be-9-1.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/898c572d-b97a-4c10-acd3-c5f4d9ad88be-9-1.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/898c572d-b97a-4c10-acd3-c5f4d9ad88be-9-1.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/898c572d-b97a-4c10-acd3-c5f4d9ad88be-9-1.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/898c572d-b97a-4c10-acd3-c5f4d9ad88be-9-1.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/898c572d-b97a-4c10-acd3-c5f4d9ad88be-9-1.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":150052,"url":"https:\/\/alphastreet.com\/india\/dr-reddys-laboratories-ltd-q1fy24-18-rise-in-profits\/","url_meta":{"origin":125277,"position":5},"title":"Dr Reddy&#8217;s Laboratories Ltd Q1FY24; 18% rise in Profits.","author":"Divyansh_Kasana","date":"July 26, 2023","format":false,"excerpt":"Dr. Reddy's Laboratories Ltd is a leading India-based pharamceutical company which offers a portfolio of products and services, including Active Pharmaceutical Ingredients (APIs), Custom Pharmaceutical services (CPS), generics, biosimilars and differentiated formulations. Financial Results: Dr Reddy's Laboratories Ltd reported Revenues for Q1FY24 of \u20b96,758.00 Crores up from \u20b95,233.00 Crore year\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/07\/image-268.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/07\/image-268.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/07\/image-268.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/07\/image-268.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/07\/image-268.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/07\/image-268.png?resize=1400%2C800&ssl=1 4x"},"classes":[]}],"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/125277","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/users\/83"}],"replies":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/comments?post=125277"}],"version-history":[{"count":0,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/125277\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media\/125269"}],"wp:attachment":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media?parent=125277"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/categories?post=125277"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/tags?post=125277"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}